Keyword: Skyrizi

AbbVie’s Skyrizi joins pharma TV spending sibling drug Humira in October list of top outlays.

AbbVie, which markets psoriasis fighters Humira and Skyrizi, launched a new digital awareness push aimed at helping patients speak up for better care.

AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?

Is AbbVie duplicating its Humira TV strategy with follow-up Skyrizi? With the first Skyrizi campaign, the Illinois company jumped quickly into TV ads.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Analysts don't expect intense FTC scrutiny of the Allergan-AbbVie combo, but no one predicted Roche's Spark delay or Celgene's forced Otezla selloff.

AbbVie is suffering from Humira biosims in Europe, but new launches could help the company backfill those losses—and Skyrizi's new numbers show how.

With longtime blockbuster Humira on the decline, AbbVie is looking to next-gen competitor Skyrizi to chip in. An OK across the pond could help.

In light of increased antitrust scrutiny over pharma M&A, AbbVie will also cut a few products to win U.S. clearance for its Allergan buyout.